Pharming Group NV
$ 17.33
-2.64%
16 Apr - close price
- Market Cap 1,257,129,000 USD
- Current Price $ 17.33
- High / Low $ 17.67 / 17.05
- Stock P/E 445.00
- Book Value 0.42
- EPS 0.04
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.01 %
- 52 Week High 21.34
- 52 Week Low 8.05
About
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Analyst Target Price
$34.60
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-10-22 | 2025-07-31 | 2025-05-06 | 2025-03-12 | 2024-10-24 | 2024-08-01 | 2024-05-08 | 2024-03-14 | 2023-10-26 | 2023-08-03 | 2023-05-11 |
| Reported EPS | 0.07 | 0.1 | 0.01 | -0.022 | 0.005 | -0.0153 | -0.0177 | -0.1851 | -0.0406 | 0.005 | 0.01 | -0.17 |
| Estimated EPS | 0.0117 | -0.125 | -0.0125 | -0.025 | 0.0085 | -0.0025 | -0.002 | 0.007 | 0.0045 | 0.01 | 0.01 | -0.17 |
| Surprise | 0.0583 | 0.225 | 0.0225 | 0.003 | -0.0035 | -0.0128 | -0.0157 | -0.1921 | -0.0451 | -0.005 | 0 | 0 |
| Surprise Percentage | 498.2906% | 180% | 180% | 12% | -41.1765% | -512% | -785% | -2744.2857% | -1002.2222% | -50% | 0% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAR
2026-04-16 17:40:21
Pharming Group N.V. has commenced the first commercial shipments of Joenja® (leniolisib) to patients in the United States, following its FDA approval. Joenja® is the first and only approved treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency. This milestone triggers a $10 million payment to Novartis under an existing license agreement, and Pharming aims to make the treatment widely available to APDS patients.
2026-04-16 13:39:07
Pharming Group N.V. announced its 2026 Annual General Meeting of Shareholders (AGM) will be held on May 28, 2026, in Oegstgeest, with a live webcast. Key agenda items include the appointment of KPMG N.V. as external auditor, amendments to non-executive directors' remuneration policy, and the renewal of board authorizations for share issuance and buybacks. These measures aim to support the company's financial reporting oversight, strategic needs, and capital structure flexibility.
2026-04-16 06:10:30
Pharming Group has announced its 2026 Annual General Meeting of Shareholders (AGM) will be held on May 28, 2026, at 14:00 CET in Oegstgeest, the Netherlands, with a live webcast option. Key agenda items include the appointment of KPMG N.V. as external auditor for 2026–2028, proposed amendments to the remuneration policy for Non-Executive Directors, and the renewal of authorizations for the Board of Directors to issue and repurchase shares. Shareholders can access meeting documents and proxy materials on the company's website under the Investors/Shareholder Meetings section.
2026-04-16 06:10:30
Pharming Group N.V. announced that its 2026 Annual General Meeting of Shareholders (AGM) will be held on Thursday, May 28, 2026, at 14:00 CET. The agenda includes proposals to appoint KPMG N.V. as the external auditor, amend the remuneration policy for Non-Executive Directors, and renew authorizations for issuing and repurchasing shares. The meeting will take place in Oegstgeest, the Netherlands, and will be webcast live.
2026-04-16 05:39:07
Pharming Group N.V. announced that its 2026 Annual General Meeting of Shareholders (AGM) will be held on Thursday, May 28, 2026, at 14:00 CET at the Corpus Congress Centre in Oegstgeest, the Netherlands. The agenda includes proposals to appoint KPMG N.V. as the external auditor, amend the remuneration policy for Non-Executive Directors, and renew authorizations for the Board of Directors to issue and repurchase shares. The meeting will also be webcast live.
2026-04-13 20:39:07
Pharming Group N.V. (PHAR) presented at the 25th Annual Needham Virtual Healthcare Conference. The company published a slide deck in conjunction with this event. The article was written by SA Transcripts, which is responsible for developing transcript-related projects and publishing thousands of quarterly earnings calls.
